Cancer is the second leading cause of human death globally. PI3K/Akt/mTOR signaling is
one of the most frequently dysregulated signaling pathways observed in cancer patients that …

Oncogenic activation of the phosphatidylinositol-3-kinase (PI3K), protein kinase B
(PKB/AKT), and mammalian target of rapamycin (mTOR) pathway is a frequent event in …

Lung cancer is one of the most common cancers and has a high mortality rate. Due to its
high incidence, the clinical management of the disease remains a major challenge. Several …

Androgen deprivation therapy (ADT) and androgen receptor (AR)-targeted therapy are the
gold standard options for treating prostate cancer (PCa). These are initially effective, as …

The introduction of second-generation androgen receptor antagonists (SG-ARAs) has
greatly impacted the treatment of metastatic prostate cancer, providing tolerable and …

The bottleneck arising from castration‐resistant prostate cancer (CRPC) treatment is its high
metastasis potential and antiandrogen drug resistance, which severely affects survival time …

The most advanced antiviral molecules addressing major SARS-CoV-2 targets (Main
protease, Spike protein, and RNA polymerase), compared with proteins of other human …

Background Despite significant advances in molecular characterization and therapeutic
targeting of advanced prostate cancer, it remains the second most common cause of cancer …

Although the prognosis of patients with localized prostate cancer is good after surgery, with
a favorable response to androgen deprivation therapy, about one third of them invariably …

PURPOSE Capivasertib is a pan-AKT inhibitor. Preclinical data indicate activity in metastatic
castration-resistant prostate cancer (mCRPC) and synergism with docetaxel. PATIENTS …